This announcement is a separate document:
四環醫藥：自願公告 - 軒竹生物自主研發1類新藥吡羅西尼單藥治療晚期乳腺癌上市申請獲國家藥監局受理
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - THE NDA OF CLASS 1 INNOVATIVE DRUG BIROCICLIB''S MONOTHERAPY, INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARM FOR THE TREATMENT OF ADVANCED BREAST CANCER, WAS ACCEPTED BY NMPA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.